Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by MasterAlgaeon Sep 17, 2020 8:44am

387 Views

Post# 31573227

Short to Medium term

The risk is mostly behind Antibe now. The next 'unknown' is business development partnerships to move the drug forward in covering the 50 million dollar cost of completing phase III trials. That of course will happen, and I'd think that such an announcement will remove the fog of uncertainty - and the market capitalization of Antibe will then begin to reflect a company entering into phase III which typically is a 600 million dollar capitalization.

<< Previous

Bullboard Posts

Next >>

Revolutionizing medical imaging with nanocarbon-based contrast drugs